SEARCH THIS WEBSITE
“By 2025, approximately 10% of adults in the UK live with atopic dermatitis, but newly integrated therapies achieve clearance rates unseen a decade ago.” – British Association of Dermatologists, 2024 insights aligned with American Academy of Dermatology updates
American Academy of Dermatology Guidelines 2025
Key Areas We Cover
- Core 2023–2024 American Academy of Dermatology guidelines with 2025 integrations
- AAD Focused Update 2025
- Four pivotal evidence-based recommendations for adult AD management
- Emerging topical and systemic therapies approved through 2025
- Practical implementation strategies for UK patients
- How The Skin Care Network in Chipping Barnet applies these guidelines
Introduction
We at The Skin Care Network incorporate the evolving guidelines for managing atopic dermatitis in adults, integrating the American Academy of Dermatology’s 2023–2024 publications, enhanced by 2025 evidence on novel therapies. These updates provide our dermatologists with targeted recommendations to improve outcomes for moderate-to-severe cases
Our experts personalise treatment plans to ensure patients benefit from the latest global standards.
Overview of the Evolving Guidelines for Atopic Dermatitis in Adults
The multidisciplinary panel, co-chaired by Dawn M. R. Davis, MD, and Robert Sidbury, MD, MPH, applies the GRADE methodology in 2023–2024, with 2025 reviews incorporating post-approval real-world data. Experts from institutions, including Mayo Clinic and Northwestern University, contribute to four new recommendations focused on FDA-approved innovations for adults
The Four Key Recommendations: 2025 Perspective
Recommendation 1: Topical Ruxolitinib Cream
We strongly recommend ruxolitinib for mild-to-moderate AD in adults who do not respond to basic emollients or corticosteroids. This selective JAK1/JAK2 inhibitor reduces itch and inflammation rapidly with twice-daily application for up to 20% body surface area. 2025 evidence from UK registries confirms sustained efficacy. We consider NICE guidance in our UK practice context
Recommendation 2: Abrocitinib Oral Therapy
We strongly recommend abrocitinib for moderate-to-severe AD refractory to topicals. This oral JAK1 inhibitor is administered daily at 100–200 mg, with appropriate baseline screenings for infections and lipids. The 2025 updates reveal improved long-term safety from extended trials
Abrocitinib Safety and Effectiveness
Recommendation 3: Upadacitinib for Persistent Cases
We recommend upadacitinib where other systemics underperform. This once-daily JAK inhibitor (15–30 mg) delivers rapid EASI-75 responses. We monitor cardiovascular and malignancy risks closely. 2025 comparative effectiveness data versus biologics like dupilumab guide our treatment decisions
Upadacitinib vs Dupilumab Study
Recommendation 4: Tralokinumab Biologic Injection
For patients preferring non-JAK options, we recommend tralokinumab. This IL-13 targeted subcutaneous therapy (300 mg every two weeks post-loading) improves quality-of-life metrics demonstrated in European cohorts
Applying 2025 Guidelines in Clinical Practice
At The Skin Care Network, we use validated assessment tools like SCORAD and DLQI to tailor patient therapies. We escalate treatment stepwise from topicals to systemics, educate patients on adherence and side-effect management, and integrate behavioural support to disrupt itch cycles. These practices align with NICE pathways and NHS standards for UK patient accessibility
Bridging Global Guidelines with Local Care in Chipping Barnet
Our Chipping Barnet clinic delivers rapid access to advanced therapies backed by on-site monitoring and continuous follow-up, applying the most current 2025 recommendations in routine clinical care.
Conclusion
The 2025 guideline perspective highlights ruxolitinib, abrocitinib, upadacitinib, and tralokinumab as cornerstone treatments, supported by high-certainty evidence to improve remission rates and quality of life for adults with atopic dermatitis.
Secure Your 2025 Atopic Dermatitis Management Plan
Contact The Skin Care Network in Barnet today to discuss personalised application of these updated guidelines. Phone +44 20 8441 1043 or book online.
FAQ
This FAQ explores the 2025-aligned American Academy of Dermatology guidelines for managing atopic dermatitis in adults, with practical insights for patients in England.
Integration of post-2024 real-world data reinforces four recommendations on ruxolitinib cream, abrocitinib, upadacitinib, and tralokinumab.
For adults with moderate-to-severe AD not controlled by topicals or phototherapy, following individual risk assessment.
Achieves significant clearance in over 50% of patients by week 16, with durable responses through 52 weeks in updated trials.
Through expert assessments in High Barnet, evidence-based prescribing, and continuous follow-up to align with GRADE standards.
